Compare LGL & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGL | KALA |
|---|---|---|
| Founded | 1917 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.1M | 5.1M |
| IPO Year | N/A | 2017 |
| Metric | LGL | KALA |
|---|---|---|
| Price | $5.68 | $0.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 8.7K | ★ 21.5M |
| Earning Date | 11-13-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 149.85 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $4,107,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.79 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.45 | $0.61 |
| 52 Week High | $9.74 | $20.60 |
| Indicator | LGL | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 43.01 | 36.22 |
| Support Level | $5.62 | $0.67 |
| Resistance Level | $5.99 | $0.86 |
| Average True Range (ATR) | 0.27 | 0.24 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 31.03 | 5.09 |
LGL Group Inc is a holding company engaged in services, merchant investment and manufacturing business activities. The company has two reportable segments; Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.